163 related articles for article (PubMed ID: 9639123)
1. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
[TBL] [Abstract][Full Text] [Related]
2. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin.
Attanoos RL; Goddard H; Thomas ND; Jasani B; Gibbs AR
Histopathology; 1995 Oct; 27(4):361-6. PubMed ID: 8847067
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.
Kortsik CS; Werner P; Freudenberg N; Virchow JC; Kroegel C; Pott M; Matthys H
Lung; 1995; 173(2):79-87. PubMed ID: 7536281
[TBL] [Abstract][Full Text] [Related]
4. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
Delahaye M; van der Ham F; van der Kwast TH
Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies.
Skov BG; Lauritzen AF; Hirsch FR; Skov T; Nielsen HW
Histopathology; 1994 Nov; 25(5):431-7. PubMed ID: 7868083
[TBL] [Abstract][Full Text] [Related]
6. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
7. The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma.
Grove A; Paulsen SM; Gregersen M
Pathol Res Pract; 1994 Nov; 190(11):1044-55. PubMed ID: 7746738
[TBL] [Abstract][Full Text] [Related]
8. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
Leers MP; Aarts MM; Theunissen PH
Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
Wirth PR; Legier J; Wright GL
Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
[TBL] [Abstract][Full Text] [Related]
12. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
13. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
14. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
Maguire B; Whitaker D; Carrello S; Spagnolo D
Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591
[TBL] [Abstract][Full Text] [Related]
16. Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology I. Prevalence of markers in tumour cell positive and negative smears.
Motherby H; Kube M; Friedrichs N; Nadjari B; Knops K; Donner A; Baschiera B; Dalquen P; Böcking A
Anal Cell Pathol; 1999; 19(1):7-20. PubMed ID: 10661621
[TBL] [Abstract][Full Text] [Related]
17. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
Skov BG; Lauritzen AF; Hirsch F; Nielsen HW
Histopathology; 1994 Jun; 24(6):553-7. PubMed ID: 8063283
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases.
Vortmeyer AO; Preuss J; Padberg BC; Kastendieck H; Schröder S
Anticancer Res; 1991; 11(2):889-94. PubMed ID: 1712181
[TBL] [Abstract][Full Text] [Related]
19. Distinction of mesothelioma from carcinoma in pleural effusions. An immunocytochemical study on routinely processed cytoblock preparations.
Kuhlmann L; Berghäuser KH; Schäffer R
Pathol Res Pract; 1991 May; 187(4):467-71. PubMed ID: 1876528
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]